Edouard Louis
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Patients with coexisting Crohn’s disease (CD) and multiple sclerosis (MS) present a complex therapeutic challenge, especially when standard dual-purpose therapies such as anti-integrins or S1P receptor modulators are contraindicated. We report the first case of a 22-year-old male successfully managed with cladribine monotherapy, achieving sustained clinical remission of both CD and MS over a four-year follow-up. Cladribine is an immune reconstitution therapy targeting T and B lymphocytes, with additional immunomodulatory effects that may benefit both conditions. This case highlights the potential of cladribine as a reliable treatment option in selected patients with concomitant CD and MS, warranting further investigation.
Year:
2025
Background and aims Probe‐based confocal endomicroscopy (pCLE) allows real‐time microscopic visualization of the intestinal mucosa surface layers. Despite remission achieved through anti‐tumor necrosis factor or vedolizumab therapy, anomalies in the intestinal epithelial barrier are observed in inflammatory bowel disease (IBD) patients. Our study aimed to assess these abnormalities in non‐IBD individuals and compare them with IBD patients in endoscopic remission to identify the associated factors. Methods The study involved 84 patients, 40 with IBD under biologic therapy for over 6 months and in endoscopic remission, and 44 without IBD or irritable bowel syndrome (IBS) undergoing colorectal screening colonoscopy. White light endoscopy and probe‐based confocal laser endomicroscopy were performed in the ileum, right colon, transverse colon, left colon, and rectum. Demographic, clinical, biological, and morphological factors were examined. Results pCLE revealed abnormalities in both non‐IBD individuals and those with IBD in endoscopic remission, such as fluorescein leakage, blood vessel dilatation, and hypervascularization across all segments, as well as epithelial gaps in the ileum, and crypt dilatation in the colon. Comparing the two groups, IBD patients exhibited slightly more gaps in the ileum, increased fluorescein leakage in the transverse colon, and fewer vessel dilatation in the transverse colon. Abnormalities were more frequent in cases of hypertension ( p = 0.03), dyslipidemia ( p = 0.02), female gender ( p = 0.02), selective serotonin reuptake inhibitor ( p = 0.03), and family history of IBD ( p = 0.04) or colorectal cancer ( p = 0.03). Conclusion Confocal endomicroscopy abnormalities are present in both non‐IBD individuals undergoing colorectal cancer screening colonoscopy as in those with IBD in endoscopic remission. Further research is needed to understand the pathophysiological mechanisms of these abnormalities and their clinical impact.
Year:
2025
Background Filgotinib is an oral, once‐daily, Janus kinase 1 preferential inhibitor approved for treatment of ulcerative colitis (UC) following the phase 2b/3 SELECTION trial. Identification of patient populations and factors associated with long‐term treatment response trajectories may improve UC management. Objective We aimed to identify and describe distinct patient subgroups of response to filgotinib based on partial Mayo Clinic Score (pMCS) trajectories over time. Methods In these post hoc analyses of SELECTION, group‐based trajectory modeling (GBTM) was applied to pMCS to describe groups of distinct, symptom‐based patient trajectories using data from patients who responded to filgotinib 200 or 100 mg and continued receiving filgotinib up to week 58. Patient demographics, disease characteristics, and week 10 response were compared between the groups. Achievement of a patient‐level multi‐component endpoint of comprehensive disease control (CDC) was assessed in each group. Results GBTM identified five distinct patient populations with different response trajectories; 67.5% of patients had beneficial trajectories. The beneficial trajectory groups generally had higher proportions of patients who were recently diagnosed ( 50% decrease in FCP from baseline). Sustained beneficial trajectory groups had a higher probability of achieving CDC at week 58 than other groups (31%–32% vs. 0%–7%). Conclusions Beneficial long‐term response trajectories and achievement of CDC with filgotinib were associated with being biologic‐naive and having less severe disease at baseline. Early estimation of sustained and CDC may facilitate patient identification and development of personalized management strategies in UC. ClinicalTrials.gov Identifier NCT02914522.
Year:
2024
Genes whose expression is affected in a consistent manner by GWAS-identified risk variants and the disease process, constitute preferred drug targets. We herein combine integrated cis-eQTL analysis in 27 blood cell populations and 43 intestinal cell types of the ileum, colon and rectum, and information on gene expression in patients, to search for putative drug targets for inflammatory bowel disease (IBD). We detect >95K cis-eQTL that affect >13K e-genes and cluster in >24K regulatory modules (RM). We uncover matching RM for 140 risk loci, implicating >300 e-genes not previously connected to IBD, and find 152 IBD-matching e-genes whose expression is perturbed in the blood or gut of patients. We identify entrectinib, a small molecule inhibiting the NRLP3 inflammasome by binding NEK7, as a promising repurposing candidate for IBD.
Year:
2024
Background Risankizumab is efficacious and well tolerated in adults with moderately to severely active Crohn's disease (CD). Aim To evaluate the corticosteroid‐sparing effect of risankizumab in CD. Methods During the 12‐week induction period, patients maintained stable baseline corticosteroid doses, up to 20 mg/day prednisone or equivalent. At week 0 of maintenance, a mandatory corticosteroid taper was started. This post hoc analysis evaluated corticosteroid‐free clinical and endoscopic outcomes at week 52 of maintenance; safety was also assessed. Results Of 889 patients randomised to induction with risankizumab 600 mg or placebo, 285 (32.1%) were taking baseline concomitant corticosteroids. Week 12 clinical remission and endoscopic response rates were greater for risankizumab 600 mg versus placebo, regardless of concomitant corticosteroid use. At week 52, 66.7%, 50.0% and 41.2% of patients taking risankizumab 180 mg, risankizumab 360 mg and (withdrawal) placebo, respectively, discontinued corticosteroids. Week 52 corticosteroid‐free clinical remission per stool frequency/abdominal pain score (risankizumab 180 mg [42.7%] or 360 mg [49.8%]; [withdrawal] placebo [39.0%]), corticosteroid‐free clinical remission per Crohn's Disease Activity Index (risankizumab 180 mg [51.0%] or 360 mg [49.5%]; [withdrawal] placebo [40.2%]), and corticosteroid‐free endoscopic response (risankizumab 180 mg [44.6%] or 360 mg [44.7%]; [withdrawal] placebo [20.7%]) rates were greater for risankizumab than placebo. Adverse event rates were generally similar, regardless of baseline corticosteroid use. Conclusions Efficacy of risankizumab 600 mg induction therapy was independent of concomitant corticosteroid use. Risankizumab 180 and 360 mg maintenance therapy yielded high rates of corticosteroid‐free clinical and endoscopic outcomes at week 52.
Year:
2024
Background. The severity of endoscopic recurrence during the first year after intestinal resection for Crohn’s disease is predictive of clinical recurrence. The aim of our study was to assess the impact of the implementation of an ileocolonoscopy during the first year after surgery on surgical recurrence. Methods. All patients who underwent a first intestinal resection for Crohn’s disease between 1992 and 2018 at the University Hospital of Liège were retrospectively included. The time to surgical recurrence was compared in three successive groups of patients operated on in the period 1992–2001 (group A), 2002–2011 (group B), and 2012–2020 (group C) using the Kaplan–Meier method and the Log-Rank test. To identify independent prognostic factors, a multivariate analysis was used via the Cox model. Results. 223 patients (group A = 69, group B = 94, group C = 60) were included. Probabilities of surgical recurrence were significantly lower in group C (2.2% and 4.7% at 3 and 5 years, respectively) compared with group B (4.2% and 7.6% at 3 and 5 years, respectively) and with group A (9% and 18.2% at 3 and 5 years, respectively) ( p = 0.0089 ). Ileocolonoscopy during the year after surgery was associated with a significantly reduced surgical recurrence rate in univariate and multivariate analysis (HR = 0.31, p = 0.0049 ). Conclusion. The implementation of an early ileocolonoscopy after surgery for Crohn’s disease since early 2000 has been associated with a reduced surgical recurrence over the last 30 years.
Year:
2022
Collaborators (13)
Alice Mayer
University of Oxford
Tadakazu Hisamatsu
-
Jean Fred Colombel
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Remo Panaccione
Director, Inflammatory Bowel disease Unit, Professor of Medicine
University of Calgary
Wouter Coppieters
senior scientist
University of Liege
Michel Georges
University of Liege
Laurent Peyrin‐Biroulet
-
Yumie Tokunaga-Mizoro
University of Liege
Emmanouil Dermitzakis
Professor
University of Geneva, Faculty of Medicine
Toshifumi Hibi
-
Yasutaka Mizoro
The University of Manchester
Stefan Schreiber
-
Marc Ferrante
-
Make your next move.
Prepare your application
Review drafts before you send them.